BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 38698462)

  • 1. Ficolin 3 promotes ferroptosis in HCC by downregulating IR/SREBP axis-mediated MUFA synthesis.
    Yuan Y; Xu J; Jiang Q; Yang C; Wang N; Liu X; Piao HL; Lu S; Zhang X; Han L; Liu Z; Cai J; Liu F; Chen S; Liu J
    J Exp Clin Cancer Res; 2024 May; 43(1):133. PubMed ID: 38698462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ZHX2 inhibits SREBP1c-mediated de novo lipogenesis in hepatocellular carcinoma via miR-24-3p.
    Yu X; Lin Q; Wu Z; Zhang Y; Wang T; Zhao S; Song X; Chen C; Wang Z; Xu L; Li C; Gao L; Liang X; Yue X; Ma C
    J Pathol; 2020 Dec; 252(4):358-370. PubMed ID: 32770671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dihydroartemisinin induces ferroptosis of hepatocellular carcinoma via inhibiting ATF4-xCT pathway.
    Ji J; Cheng Z; Zhang J; Wu J; Xu X; Guo C; Feng J
    J Cell Mol Med; 2024 Apr; 28(8):e18335. PubMed ID: 38652216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stearoyl-CoA Desaturase Promotes Liver Fibrosis and Tumor Development in Mice via a Wnt Positive-Signaling Loop by Stabilization of Low-Density Lipoprotein-Receptor-Related Proteins 5 and 6.
    Lai KKY; Kweon SM; Chi F; Hwang E; Kabe Y; Higashiyama R; Qin L; Yan R; Wu RP; Lai K; Fujii N; French S; Xu J; Wang JY; Murali R; Mishra L; Lee JS; Ntambi JM; Tsukamoto H
    Gastroenterology; 2017 May; 152(6):1477-1491. PubMed ID: 28143772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of ACADM-Mediated Fatty Acid Oxidation Promotes Hepatocellular Carcinoma via Aberrant CAV1/SREBP1 Signaling.
    Ma APY; Yeung CLS; Tey SK; Mao X; Wong SWK; Ng TH; Ko FCF; Kwong EML; Tang AHN; Ng IO; Cai SH; Yun JP; Yam JWP
    Cancer Res; 2021 Jul; 81(13):3679-3692. PubMed ID: 33975883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD147 reprograms fatty acid metabolism in hepatocellular carcinoma cells through Akt/mTOR/SREBP1c and P38/PPARα pathways.
    Li J; Huang Q; Long X; Zhang J; Huang X; Aa J; Yang H; Chen Z; Xing J
    J Hepatol; 2015 Dec; 63(6):1378-89. PubMed ID: 26282231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorafenib kills liver cancer cells by disrupting SCD1-mediated synthesis of monounsaturated fatty acids
    Liu G; Kuang S; Cao R; Wang J; Peng Q; Sun C
    FASEB J; 2019 Sep; 33(9):10089-10103. PubMed ID: 31199678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of ficolin-3 expression is associated with poor prognosis in patients with hepatocellular carcinoma.
    Chen CC; Yu TH; Wu CC; Hung WC; Lee TL; Tang WH; Tsai IT; Chung FM; Lee YJ; Hsu CC
    Int J Med Sci; 2023; 20(8):1091-1096. PubMed ID: 37484802
    [No Abstract]   [Full Text] [Related]  

  • 9. Pleiotrophin, a target of miR-384, promotes proliferation, metastasis and lipogenesis in HBV-related hepatocellular carcinoma.
    Bai PS; Xia N; Sun H; Kong Y
    J Cell Mol Med; 2017 Nov; 21(11):3023-3043. PubMed ID: 28557334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DDX39B facilitates the malignant progression of hepatocellular carcinoma via activation of SREBP1-mediated de novo lipid synthesis.
    Feng T; Li S; Zhao G; Li Q; Yuan H; Zhang J; Gu R; Ou D; Guo Y; Kou Q; Wang Q; Li K; Lin P
    Cell Oncol (Dordr); 2023 Oct; 46(5):1235-1252. PubMed ID: 37052853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ACSL4 reprograms fatty acid metabolism in hepatocellular carcinoma via c-Myc/SREBP1 pathway.
    Chen J; Ding C; Chen Y; Hu W; Yu C; Peng C; Feng X; Cheng Q; Wu W; Lu Y; Xie H; Zhou L; Wu J; Zheng S
    Cancer Lett; 2021 Apr; 502():154-165. PubMed ID: 33340617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bufalin Inhibits Tumorigenesis and SREBP-1-Mediated Lipogenesis in Hepatocellular Carcinoma via Modulating the ATP1A1/CA2 Axis.
    Huang CJ; Zhang CY; Zhao YK; Wang D; Zhuang L; Qian L; Xie L; Zhu Y; Meng ZQ
    Am J Chin Med; 2023; 51(2):461-485. PubMed ID: 36655687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FCN3 inhibits the progression of hepatocellular carcinoma by suppressing SBDS-mediated blockade of the p53 pathway.
    Ma D; Liu P; Wen J; Gu Y; Yang Z; Lan J; Fan H; Liu Z; Guo D
    Int J Biol Sci; 2023; 19(2):362-376. PubMed ID: 36632465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA-21 is a potential link between non-alcoholic fatty liver disease and hepatocellular carcinoma via modulation of the HBP1-p53-Srebp1c pathway.
    Wu H; Ng R; Chen X; Steer CJ; Song G
    Gut; 2016 Nov; 65(11):1850-1860. PubMed ID: 26282675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. APE1 inhibition enhances ferroptotic cell death and contributes to hepatocellular carcinoma therapy.
    Du Y; Zhou Y; Yan X; Pan F; He L; Guo Z; Hu Z
    Cell Death Differ; 2024 Apr; 31(4):431-446. PubMed ID: 38418695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The hypoxia conditioned mesenchymal stem cells promote hepatocellular carcinoma progression through YAP mediated lipogenesis reprogramming.
    Liu Y; Ren H; Zhou Y; Shang L; Zhang Y; Yang F; Shi X
    J Exp Clin Cancer Res; 2019 May; 38(1):228. PubMed ID: 31142342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma.
    Calvisi DF; Wang C; Ho C; Ladu S; Lee SA; Mattu S; Destefanis G; Delogu S; Zimmermann A; Ericsson J; Brozzetti S; Staniscia T; Chen X; Dombrowski F; Evert M
    Gastroenterology; 2011 Mar; 140(3):1071-83. PubMed ID: 21147110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ZNF498 promotes hepatocellular carcinogenesis by suppressing p53-mediated apoptosis and ferroptosis via the attenuation of p53 Ser46 phosphorylation.
    Zhang X; Zheng Q; Yue X; Yuan Z; Ling J; Yuan Y; Liang Y; Sun A; Liu Y; Li H; Xu K; He F; Wang J; Wu J; Zhao C; Tian C
    J Exp Clin Cancer Res; 2022 Feb; 41(1):79. PubMed ID: 35227287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncogenic activation of PI3K-AKT-mTOR signaling suppresses ferroptosis via SREBP-mediated lipogenesis.
    Yi J; Zhu J; Wu J; Thompson CB; Jiang X
    Proc Natl Acad Sci U S A; 2020 Dec; 117(49):31189-31197. PubMed ID: 33229547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tetrahydropalmatine ameliorates hepatic steatosis in nonalcoholic fatty liver disease by switching lipid metabolism via AMPK-SREBP-1c-Sirt1 signaling axis.
    Yin X; Liu Z; Wang J
    Phytomedicine; 2023 Oct; 119():155005. PubMed ID: 37562090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.